RxDoctor Payments Data

Ryan Burton, MD

Ophthalmology · Mobile, ALNPI 1578854766

Payments from drug & device makers

$1,416in general payments, 2019–2025

Across 59 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$454
  • Alcon$261
  • Aerie Pharmaceuticals, Inc.$163
  • Sight Sciences, Inc.$146
  • Iridex Corporation$76
  • Bausch & Lomb Americas Inc.$61
  • plus $253 from 7 others

What the payments were for

  • Food & beverage$1,416100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,416 in reported general payments places this provider in the 40th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$332,494
Medicare patients
851
Services billed
3,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost185$86,460
RocklatanNetarsudil Mesylat/Latanoprost177$82,460
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol216$38,623
RestasisCyclosporine41$36,900
Latanoprost3,339$31,819
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,567$26,061
CombiganBrimonidine Tartrate/Timolol74$25,650
Prednisolone Acetate477$24,898
Travoprost105$19,988
VyzultaLatanoprostene Bunod47$18,061
RhopressaNetarsudil Mesylate29$15,071
Brimonidine Tartrate857$11,233
XiidraLifitegrast14$10,982
Ketorolac Tromethamine403$9,163
Cyclosporine23$8,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$454$152,690311 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$163$97,531206 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$61$29,04361 claims
AlconSimbrinza$261$4,35821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →